Trial
NCT02760602
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Solanezumab
Why stopped
Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-10